Status:
WITHDRAWN
Efficacy of Atomoxetine Therapy Versus Placebo for Cognitive Late Effects
Lead Sponsor:
Temple University
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Cancer
Cognitive Late Effects
Eligibility:
All Genders
6-18 years
Phase:
PHASE3
Brief Summary
The purpose of the study is to evaluate the effectiveness and safety of atomoxetine in enhancing attention and concentration among childhood survivors of cancer.
Detailed Description
In previous years, it had often been assumed that cognitive and behavioral declines in children who survived cancer therapy were largely a function of the prophylactic therapies (e.g., radiation, chem...
Eligibility Criteria
Inclusion
- Age 6-18
- Patient has received chemotherapy, radiation, or a combination of both.
- Patient is at least 12 months post-competion of therapy but no more than five years post-completion of therapy.
Exclusion
- No ongoing pharmacological management of ADHD
- Not currently pregnant
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00255138
Start Date
November 1 2005
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Temple University
Philadelphia, Pennsylvania, United States, 19140